Search

Displaying results 3131 - 3140 of 5263 in total
  1. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  2. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    [A254222] Plasmepsins are aspartyl proteases produced by the malaria parasite _Plasmodium falciparum_, and PMX is considered to be essential for parasite egress and invasion. … It has shown high potency in biochemical (IC<sub>50</sub> = 7 nM), _in vitro_ (_P. falciparum_ 3D7 lactate dehydrogenase growth inhibition assay IC<sub>50</sub> = 10 nM), and _in vivo_ (50 mg/kg dose

  3. Drug

    Teglarinad chloride

    go.drugbank.com/drugs/DB05217
    Investigational

    Although the exact mechanism of action has yet to be fully elucidated, GMX1778 appears to antagonize nuclear factor-kappa B (NF-kB) transcription, resulting in the induction of tumor cell apoptosis.

  4. Drug

    Glisoxepide

    go.drugbank.com/drugs/DB01289
    Investigational

    by sulphate. … Glisoxepide uptake could be further inhibited by blockers of the hepatocellular monocarboxylate transporter, by the loop diuretic bumetanide, by 4,4'-diisothiocyano-2,2'-stilbenedisulfonate (DIDS) and

  5. Drug

    Amiloxate

    go.drugbank.com/drugs/DB11207
    Approved

    Amiloxate is an EMA-approved chemical UV-filter found in over-the-counter sunscreen products at concentrations up to 10%m . It is often referred to as isoamyl 4-methoxycinnamate or isoamyl p-methoxycinnamate. Amiloxate is a cinnamic acid...

    Mixtures: Dpc Pink Aura Cushion No.21, Dpc Pink Aura Cushion No.23
  6. Drug

    Sarilumab

    go.drugbank.com/drugs/DB11767
    ApprovedInvestigational

    [A27265] RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. … [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid

  7. Drug

    Verpasep caltespen

    go.drugbank.com/drugs/DB04959
    Investigational

    Verpasep caltespen is a recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from _Mycobacterium bovis_, and the human papilloma viral (HPV) protein E7. … It is being developed by StressGen Biotechnologies Corp.

  8. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. … Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis

  9. Drug

    Elesclomol

    go.drugbank.com/drugs/DB05719
    Investigational

    It is being developed by Synta Pharmaceuticals. … Elesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death.

    Synonyms: 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide
  10. Drug

    3,5-Diiodotyrosine

    go.drugbank.com/drugs/DB03374
    Experimental

    A product from the iodination of MONOIODOTYROSINE. … In the biosynthesis of thyroid hormones, diiodotyrosine residues are coupled with other monoiodotyrosine or diiodotyrosine residues to form T4 or T3 thyroid hormones (THYROXINE and TRIIODOTHYRONINE).